RT Journal Article
SR Electronic
T1 A multiplex microsphere IgG assay for SARS-CoV-2 using ACE2-mediated inhibition as a surrogate for neutralization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.05.20203976
DO 10.1101/2020.10.05.20203976
A1 Andrew Cameron
A1 Claire A. Porterfield
A1 Larry D. Byron
A1 Jiong Wang
A1 Zachary Pearson
A1 Jessica L. Bohrhunter
A1 Anthony B. Cardillo
A1 Lindsay Ryan-Muntz
A1 Ryan A. Sorensen
A1 Mary T. Caserta
A1 Steven Angeloni
A1 Dwight J. Hardy
A1 Martin S. Zand
A1 Nicole D. Pecora
YR 2020
UL http://medrxiv.org/content/early/2020/10/06/2020.10.05.20203976.abstract
AB The COVID-19 pandemic has highlighted the challenges inherent to the serological detection of a novel pathogen such as SARS-CoV-2. Serological tests can be used diagnostically and for surveillance, but their usefulness depends on their throughput, sensitivity and specificity. Here, we describe a multiplex fluorescent microsphere-based assay, 3Flex, that can detect antibodies to three major SARS-CoV-2 antigens—spike (S) protein, the spike ACE2 receptor-binding domain (RBD), and nucleocapsid (NP). Specificity was assessed using 213 pre-pandemic samples. Sensitivity was measured and compared to the Abbott™ ARCHITECT™ SARS-CoV-2 IgG assay using serum samples from 125 unique patients equally binned (n = 25) into 5 time intervals (≤5, 6 to 10, 11 to 15, 16 to 20, and ≥21 days from symptom onset). With samples obtained at ≤5 days from symptom onset, the 3Flex assay was more sensitive (48.0% vs. 32.0%), but the two assays performed comparably using serum obtained ≥21 days from symptom onset. A larger collection (n = 534) of discarded sera was profiled from patients (n = 140) whose COVID-19 course was characterized through chart review. This revealed the relative rise, peak (S, 23.8; RBD, 23.6; NP, 16.7; in days from symptom onset), and decline of the antibody response. Considerable interperson variation was observed with a subset of extensively sampled ICU patients. Using soluble ACE2, inhibition of antibody binding was demonstrated for S and RBD, and not for NP. Taken together, this study described the performance of an assay built on a flexible and high-throughput serological platform that proved adaptable to the emergence of a novel infectious agent.Competing Interest StatementS.A. is an employee of Luminex. N.P received some support for the purchase of reagents and supplies from Luminex. Luminex played no role in the design of the study, analysis of data, or writing of the manuscript.Funding StatementFunding from the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center supported this study. This study was also partially supported by the National Institutes of Health Institute of Allergy, Immunology and Infectious Diseases grantsR21 AI138500 and R01 AI129518 (MZ, JW) and the University of Rochester Clinical and Translational Science Award UL1 TR002001 from the National Center for Advancing Translational Sciences of the National Institutes of Health (MZ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the URMC IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll manuscript data is available as an attached data set.